Seamless Viral-Vector Technology Transfer at Any Phase: Offering Stability in Times of Change

This presentation features Ramin Baghirzade, senior director and global head of commercial gene therapy services, Charles River Laboratories, who described two common interactions that cause friction between the two entities: Sometimes drug developers approach CDMOs to create products with only gene-of-interest (GoI) sequences prepared. And in another scenario, drug developers already running clinical trials require more or different materials and reach out to a CDMO for help.

Register or Login and hit Watch on Demand to view the recorded webcast now.